Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

HER2 mutations are a known factor in several cancers, including breast and gastric cancers. In lung cancer-particularly NSCLC-these mutations are less common but remain clinically significant.

Dr Rugo discusses the promising outcomes of trastuzumab deruxtecan for HER2+ breast cancer, addressing interstitial lung disease risks and retreatment strategies.

They report in Cell Reports Medicine that conducting an integrated proteogenomic profiling of cancer cells, which combines the analysis of DNA, RNA, protein and phosphoprotein data, revealed two novel ...

CHICAGO – Investigational HER3-targeted antibody-drug conjugates and bispecifics showed promising efficacy in heavily pretreated non-small cell lung cancer patients harboring classical EGFR activating ...

Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent ...

U.S. FDA Accepts New Drug Application Under Priority Review for sevabertinib (BAY 2927088) in HER2-Mutant Non-Small Cell Lung Cancer ...

HER2 mutations are typically associated with breast and gastric cancers but make up around 2% of lung cancer patients, typically in those who never smoked.